We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

133 hedge funds and large institutions have $815M invested in Aclaris Therapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,826% more call options, than puts

Call options by funds: $2.15M | Put options by funds: $31K

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

32% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 37

6% more funds holding

Funds holding: 126 → 133 (+7)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

1.22% less ownership

Funds ownership: 92.76% → 91.53% (-1.2%)

20% less capital invested

Capital invested by funds: $1.02B → $815M (-$208M)

Holders
133
Holders Change
+7
Holders Change %
+5.56%
% of All Funds
2.05%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
28
Increased
49
Reduced
37
Closed
19
Calls
$2.15M
Puts
$31K
Net Calls
+$2.12M
Net Calls Change
+$595K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$9.43M
2
CC
Commodore Capital
New York
+$7.3M
3
O
OrbiMed
New York
+$5.06M
4
BI
BVF Inc
California
+$4.89M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$4.61M

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
-$35.2M
2
WP
Woodline Partners
California
-$10.7M
3
CAM
Cormorant Asset Management
Massachusetts
-$9.09M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$8.52M
5
Invesco
Invesco
Georgia
-$6.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$9.35M +$3.81M +251,600 +64%
ACM
27
Aisling Capital Management
New York
$9.22M – – –
SSA
28
Schonfeld Strategic Advisors
New York
$7.13M -$340K -22,415 -4%
Northern Trust
29
Northern Trust
Illinois
$7.12M -$179K -11,837 -2%
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$6.78M +$4.61M +304,557 +188%
FM
31
Frazier Management
Washington
$5.94M – – –
AAA
32
Affinity Asset Advisors
New York
$5.82M +$758K +50,000 +14%
Millennium Management
33
Millennium Management
New York
$5.13M +$474K +31,316 +10%
GTC
34
Ghost Tree Capital
New York
$4.73M +$758K +50,000 +18%
N
35
Nuveen
North Carolina
$4.39M +$456K +30,066 +11%
SCM
36
Silverarc Capital Management
Massachusetts
$4.16M +$1.71M +112,899 +65%
Deutsche Bank
37
Deutsche Bank
Germany
$3.69M -$1.04M -68,368 -21%
Goldman Sachs
38
Goldman Sachs
New York
$3.22M -$3.33M -219,902 -50%
DGM
39
Darwin Global Management
Jersey
$3.14M +$860K +56,750 +36%
IHAM
40
Integral Health Asset Management
New York
$2.91M +$227K +15,000 +8%
ACM
41
Asymmetry Capital Management
California
$2.89M -$655K -43,208 -18%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$2.71M +$61.8K +4,077 +2%
Verition Fund Management
43
Verition Fund Management
Connecticut
$2.59M +$2.7M +178,310 New
Charles Schwab
44
Charles Schwab
California
$1.88M +$30.3K +1,997 +2%
HS
45
HighVista Strategies
Massachusetts
$1.63M +$290K +19,160 +21%
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.47M +$57.6K +3,800 +4%
Barclays
47
Barclays
United Kingdom
$1.46M +$763K +50,349 +100%
ACP
48
Acuta Capital Partners
California
$1.43M -$649K -42,839 -30%
HLA
49
Hamilton Lane Advisors
Pennsylvania
$1.42M +$1.48M +97,550 New
Ameriprise
50
Ameriprise
Minnesota
$1.08M +$1.13M +74,258 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q4 2021 in Review

133 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2021, worth a combined $815M — down 20% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ACRS positions and 19 closed out — a net gain of 9 holders — while 49 added to existing stakes and 37 trimmed.

The largest buyer was Laurion Capital Management, adding an estimated $9.43M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $35.2M sold.

  • 133 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2021, up from 126 in Q3 2021.
  • Funds reported $815M of Aclaris Therapeutics stock for Q4 2021, down 20% quarter-over-quarter.
  • 28 funds opened new Aclaris Therapeutics positions in Q4 2021 and 19 closed out, a net change of +9 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2021 was Laurion Capital Management, an estimated $9.43M added.
  • The largest Aclaris Therapeutics seller in Q4 2021 was Foresite Capital Management III, an estimated $35.2M sold.

Based on aggregated 13F filings for Q4 2021.